The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study

Background and Design: secukinumab is an effective treatment option in moderate-to-severe plaque type psoriasis. However, there are a few real-life data studies comparing the efficacy of 150 mg and 300 mg dosages. The aim of this study was to evaluate the efficacy and safety of secukinumab at 150 mg and 300 mg in dinical practice in chronic plaque type psoriasis patients attending our center. Materials and Methods: The medical records of 33 patients consecutively treated with secukinumab 150 mg or 300 mg for a minimum three-month period were analyzed retrospectively. Treatment response was defined as the achievement of a minimum psoriasis area and severity index (PASI) 75 response at week 12. Results: Eighteen (55.5%) of the patients were men. The mean duration of the disease was 20 +/- 9.38 (1-40) years. Most (75.7%) patients had previously received at least one biological therapy. Seventeen patients were treated with 300 mg and 14 with 150 mg during the induction and maintenance periods. Two patients received induction therapy at 150 mg and maintenance therapy at 300 mg. At week 12, PASI 75, 90, and 100 responses were achieved in 78.8%, 66.7%, and 22.3% of patients, respectively. Treatment responses were similar between patients receiving 150 mg and 300 mg, and also between biologic naive and non-naive patients (p>0.05). Adverse events were observed in three patients, but these did not necessitate discontinuation of therapy. Conclusion: Secukinumab at doses of 150 mg and 300 mg is a fast-acting, effective and safe treatment option in patients with chronic plaque type psoriasis, both biologic naive and non-naive.